Search > Fatty Liver Disease
150 Participants NeededMy employer runs this trial

Rezdiffra for Fatty Liver Disease

Recruiting at 15 trial locations
TH
Overseen ByTom Hare
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Madrigal Pharmaceuticals, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

What You Need to Know Before You Apply

What is the purpose of this trial?

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)

Who Is on the Research Team?

TH

Tom Hare

Principal Investigator

Madrigal Pharmaceuticals, Inc.

Are You a Good Fit for This Trial?

This trial is for adults (18+) with fatty liver disease (MASH) and moderate-to-advanced liver scarring (F2-F3 fibrosis), but not cirrhosis. Participants must have stable health, be on a steady dose of either Farxiga or Actos for at least 2 months, and meet other medication safety requirements.

Inclusion Criteria

I am willing to join the study and sign a consent form.
I meet all the requirements for REZDIFFRA as determined by my doctor.
I am 18 years old or older.
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • ACTOS/pioglitazone
  • FARXIGA/dapagliflozin
  • Rezdiffra (Resmetirom)

Trial Overview

The study tests the safety of Rezdiffra (Resmetirom) when used together with common diabetes medications—Farxiga (dapagliflozin) or Actos (pioglitazone)—in people with MASH and F2-F3 fibrosis. It observes how these drugs work together in real-world conditions.

How Is the Trial Designed?

6

Treatment groups

Experimental Treatment

Group I: REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New]Experimental Treatment2 Interventions
Group II: REZDIFFRA [Ongoing] | Actos (pioglitazone) [New]Experimental Treatment2 Interventions
Group III: Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New]Experimental Treatment2 Interventions
Group IV: Farxiga (dapagliflozin) [New] | Resmetirom [New]Experimental Treatment2 Interventions
Group V: Actos (pioglitazone) [Ongoing] | Resmetirom [New]Experimental Treatment2 Interventions
Group VI: Actos (pioglitazone) [New] | Resmetirom [New]Experimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Madrigal Pharmaceuticals, Inc.

Lead Sponsor

Trials
16
Recruited
5,400+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.